| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
723.09(B) |
| Last
Volume: |
3,201,799 |
Avg
Vol: |
3,291,238 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
435,750 |
871,420 |
2,951,506 |
6,211,418 |
| Total Sell Value |
$330,574,311 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
5 |
14 |
46 |
89 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Yuffa Ilya |
EVP & President, LLY Intl |
• – – |
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,702 |
16,676 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-31 |
4 |
S |
$645.28 |
$50,920,924 |
D/D |
(78,573) |
99,333,810 |
|
-20% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-30 |
4 |
S |
$645.11 |
$49,175,200 |
D/D |
(76,215) |
99,412,383 |
|
-20% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-29 |
4 |
S |
$645.07 |
$34,854,422 |
D/D |
(54,032) |
99,488,598 |
|
-20% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-16 |
4 |
S |
$645.55 |
$761,806 |
D/D |
(1,180) |
99,542,630 |
|
-22% |
|
| Luciano Juan R |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$14,595 |
D/D |
23 |
15,592 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$12,057 |
D/D |
19 |
53,891 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$10,153 |
D/D |
16 |
2,085 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$10,153 |
D/D |
16 |
1,437 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$9,519 |
D/D |
15 |
2,584 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-11 |
4 |
S |
$630.24 |
$7,827,686 |
D/D |
(12,344) |
99,543,810 |
|
-22% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-10 |
4 |
S |
$630.19 |
$103,246,373 |
D/D |
(163,730) |
99,556,154 |
|
-23% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-09 |
4 |
S |
$630.39 |
$21,821,413 |
D/D |
(34,538) |
99,719,884 |
|
-24% |
|
| Lilly Endowment Inc |
|
– – • |
2024-01-04 |
4 |
S |
$630.24 |
$9,068,445 |
D/D |
(14,388) |
99,754,422 |
|
-26% |
|
| Johnson Kimberly H |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$9,856 |
D/D |
17 |
2,569 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$9,856 |
D/D |
17 |
71,886 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$5,218 |
D/D |
9 |
2,069 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$9,856 |
D/D |
17 |
1,421 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$14,494 |
D/D |
25 |
15,569 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-12-18 |
4 |
A |
$579.76 |
$11,595 |
D/D |
20 |
53,872 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-12-01 |
4 |
D |
$591.04 |
$1,266,008 |
D/D |
(2,142) |
7,376 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,810 |
9,518 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$200,196 |
D/D |
335 |
8,794 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$211,550 |
D/D |
354 |
53,751 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$209,758 |
D/D |
351 |
2,548 |
|
- |
|
3297 Records found
|
|
Page 3 of 132 |
|
|
20.84 (2.68%) 
